Fmr LLC Grows Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Fmr LLC lifted its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 283.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 45,393 shares of the biopharmaceutical company’s stock after purchasing an additional 33,546 shares during the period. Fmr LLC’s holdings in Agios Pharmaceuticals were worth $2,017,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Acadian Asset Management LLC purchased a new position in Agios Pharmaceuticals in the second quarter valued at $37,000. Quest Partners LLC purchased a new position in Agios Pharmaceuticals in the second quarter valued at $40,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 363 shares during the period. CWM LLC boosted its holdings in Agios Pharmaceuticals by 554.7% in the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 1,836 shares during the period. Finally, North Star Asset Management Inc. purchased a new position in Agios Pharmaceuticals in the second quarter valued at $216,000.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on AGIO shares. Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Scotiabank lifted their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Royal Bank of Canada lifted their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Finally, StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $56.33.

Insider Transactions at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now owns 20,158 shares in the company, valued at approximately $988,346.74. The trade was a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Stock Performance

AGIO opened at $38.97 on Friday. The business’s 50-day simple moving average is $50.02 and its 200-day simple moving average is $46.70. Agios Pharmaceuticals, Inc. has a one year low of $20.96 and a one year high of $62.58. The stock has a market capitalization of $2.22 billion, a P/E ratio of 3.43 and a beta of 0.80.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.